nodes	percent_of_prediction	percent_of_DWPC	metapath
Regadenoson—Cytarabine—POLD1—uterine cancer	0.0239	0.378	CrCbGaD
Regadenoson—Clofarabine—RRM2—uterine cancer	0.0152	0.241	CrCbGaD
Regadenoson—Adenosine triphosphate—ABCC9—uterine cancer	0.0102	0.162	CrCbGaD
Regadenoson—Cladribine—RRM2—uterine cancer	0.00874	0.138	CrCbGaD
Regadenoson—Adenosine triphosphate—AKT1—uterine cancer	0.00507	0.0804	CrCbGaD
Regadenoson—Arthralgia—Medroxyprogesterone Acetate—uterine cancer	0.00353	0.00376	CcSEcCtD
Regadenoson—Chest pain—Medroxyprogesterone Acetate—uterine cancer	0.00353	0.00376	CcSEcCtD
Regadenoson—Anxiety—Medroxyprogesterone Acetate—uterine cancer	0.00351	0.00375	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Medroxyprogesterone Acetate—uterine cancer	0.0035	0.00374	CcSEcCtD
Regadenoson—Hypotension—Progesterone—uterine cancer	0.00348	0.00372	CcSEcCtD
Regadenoson—Discomfort—Medroxyprogesterone Acetate—uterine cancer	0.00348	0.00372	CcSEcCtD
Regadenoson—Flushing—Dactinomycin—uterine cancer	0.00344	0.00368	CcSEcCtD
Regadenoson—Vasodilation—Epirubicin—uterine cancer	0.00341	0.00364	CcSEcCtD
Regadenoson—Vasodilation procedure—Epirubicin—uterine cancer	0.00341	0.00364	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Progesterone—uterine cancer	0.0034	0.00363	CcSEcCtD
Regadenoson—Injection site pain—Doxorubicin—uterine cancer	0.0034	0.00363	CcSEcCtD
Regadenoson—Anaphylactic shock—Medroxyprogesterone Acetate—uterine cancer	0.00338	0.00361	CcSEcCtD
Regadenoson—Insomnia—Progesterone—uterine cancer	0.00337	0.0036	CcSEcCtD
Regadenoson—Paraesthesia—Progesterone—uterine cancer	0.00335	0.00357	CcSEcCtD
Regadenoson—Dyspnoea—Progesterone—uterine cancer	0.00332	0.00355	CcSEcCtD
Regadenoson—Shock—Medroxyprogesterone Acetate—uterine cancer	0.00332	0.00355	CcSEcCtD
Regadenoson—Somnolence—Progesterone—uterine cancer	0.00332	0.00354	CcSEcCtD
Regadenoson—Nervous system disorder—Medroxyprogesterone Acetate—uterine cancer	0.00331	0.00354	CcSEcCtD
Regadenoson—Bronchospasm—Etoposide—uterine cancer	0.0033	0.00352	CcSEcCtD
Regadenoson—Tachycardia—Medroxyprogesterone Acetate—uterine cancer	0.0033	0.00352	CcSEcCtD
Regadenoson—Skin disorder—Medroxyprogesterone Acetate—uterine cancer	0.00328	0.0035	CcSEcCtD
Regadenoson—Hyperhidrosis—Medroxyprogesterone Acetate—uterine cancer	0.00327	0.00349	CcSEcCtD
Regadenoson—Erythema—Dactinomycin—uterine cancer	0.00323	0.00345	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Progesterone—uterine cancer	0.00322	0.00344	CcSEcCtD
Regadenoson—Pain—Progesterone—uterine cancer	0.00319	0.0034	CcSEcCtD
Regadenoson—Hypotension—Medroxyprogesterone Acetate—uterine cancer	0.00316	0.00337	CcSEcCtD
Regadenoson—Vasodilation—Doxorubicin—uterine cancer	0.00316	0.00337	CcSEcCtD
Regadenoson—Vasodilation procedure—Doxorubicin—uterine cancer	0.00316	0.00337	CcSEcCtD
Regadenoson—Atrioventricular block—Epirubicin—uterine cancer	0.00309	0.0033	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Medroxyprogesterone Acetate—uterine cancer	0.00308	0.00329	CcSEcCtD
Regadenoson—Feeling abnormal—Progesterone—uterine cancer	0.00307	0.00328	CcSEcCtD
Regadenoson—Insomnia—Medroxyprogesterone Acetate—uterine cancer	0.00306	0.00326	CcSEcCtD
Regadenoson—Gastrointestinal pain—Progesterone—uterine cancer	0.00305	0.00326	CcSEcCtD
Regadenoson—Paraesthesia—Medroxyprogesterone Acetate—uterine cancer	0.00303	0.00324	CcSEcCtD
Regadenoson—Musculoskeletal pain—Epirubicin—uterine cancer	0.00303	0.00324	CcSEcCtD
Regadenoson—Dyspnoea—Medroxyprogesterone Acetate—uterine cancer	0.00301	0.00322	CcSEcCtD
Regadenoson—Somnolence—Medroxyprogesterone Acetate—uterine cancer	0.003	0.00321	CcSEcCtD
Regadenoson—Ill-defined disorder—Dactinomycin—uterine cancer	0.003	0.0032	CcSEcCtD
Regadenoson—Urticaria—Progesterone—uterine cancer	0.00296	0.00316	CcSEcCtD
Regadenoson—Acute coronary syndrome—Etoposide—uterine cancer	0.00295	0.00315	CcSEcCtD
Regadenoson—Abdominal pain—Progesterone—uterine cancer	0.00295	0.00315	CcSEcCtD
Regadenoson—Renal failure—Etoposide—uterine cancer	0.00294	0.00314	CcSEcCtD
Regadenoson—Myocardial infarction—Etoposide—uterine cancer	0.00293	0.00313	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Medroxyprogesterone Acetate—uterine cancer	0.00292	0.00311	CcSEcCtD
Regadenoson—Malaise—Dactinomycin—uterine cancer	0.00291	0.00311	CcSEcCtD
Regadenoson—Atrioventricular block—Doxorubicin—uterine cancer	0.00286	0.00305	CcSEcCtD
Regadenoson—Musculoskeletal pain—Doxorubicin—uterine cancer	0.00281	0.003	CcSEcCtD
Regadenoson—Feeling abnormal—Medroxyprogesterone Acetate—uterine cancer	0.00278	0.00297	CcSEcCtD
Regadenoson—Gastrointestinal pain—Medroxyprogesterone Acetate—uterine cancer	0.00276	0.00295	CcSEcCtD
Regadenoson—Myalgia—Dactinomycin—uterine cancer	0.00275	0.00294	CcSEcCtD
Regadenoson—Hypersensitivity—Progesterone—uterine cancer	0.00275	0.00293	CcSEcCtD
Regadenoson—Discomfort—Dactinomycin—uterine cancer	0.00272	0.0029	CcSEcCtD
Regadenoson—Urticaria—Medroxyprogesterone Acetate—uterine cancer	0.00268	0.00287	CcSEcCtD
Regadenoson—Asthenia—Progesterone—uterine cancer	0.00268	0.00286	CcSEcCtD
Regadenoson—Hypoaesthesia—Etoposide—uterine cancer	0.00267	0.00285	CcSEcCtD
Regadenoson—Abdominal pain—Medroxyprogesterone Acetate—uterine cancer	0.00267	0.00285	CcSEcCtD
Regadenoson—Diarrhoea—Progesterone—uterine cancer	0.00255	0.00272	CcSEcCtD
Regadenoson—Eye disorder—Etoposide—uterine cancer	0.00251	0.00268	CcSEcCtD
Regadenoson—Flushing—Etoposide—uterine cancer	0.00249	0.00266	CcSEcCtD
Regadenoson—Cardiac disorder—Etoposide—uterine cancer	0.00249	0.00266	CcSEcCtD
Regadenoson—Hypersensitivity—Medroxyprogesterone Acetate—uterine cancer	0.00249	0.00266	CcSEcCtD
Regadenoson—Dizziness—Progesterone—uterine cancer	0.00247	0.00263	CcSEcCtD
Regadenoson—Angiopathy—Etoposide—uterine cancer	0.00244	0.0026	CcSEcCtD
Regadenoson—Immune system disorder—Etoposide—uterine cancer	0.00243	0.00259	CcSEcCtD
Regadenoson—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.00242	0.00259	CcSEcCtD
Regadenoson—Mediastinal disorder—Etoposide—uterine cancer	0.00242	0.00258	CcSEcCtD
Regadenoson—Eye pain—Epirubicin—uterine cancer	0.00241	0.00257	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Dactinomycin—uterine cancer	0.0024	0.00256	CcSEcCtD
Regadenoson—Vomiting—Progesterone—uterine cancer	0.00237	0.00253	CcSEcCtD
Regadenoson—Rash—Progesterone—uterine cancer	0.00235	0.00251	CcSEcCtD
Regadenoson—Dermatitis—Progesterone—uterine cancer	0.00235	0.00251	CcSEcCtD
Regadenoson—Headache—Progesterone—uterine cancer	0.00234	0.00249	CcSEcCtD
Regadenoson—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	0.00231	0.00247	CcSEcCtD
Regadenoson—Dysgeusia—Etoposide—uterine cancer	0.00229	0.00244	CcSEcCtD
Regadenoson—Renal impairment—Epirubicin—uterine cancer	0.00229	0.00244	CcSEcCtD
Regadenoson—Pain—Dactinomycin—uterine cancer	0.00225	0.00241	CcSEcCtD
Regadenoson—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.00223	0.00239	CcSEcCtD
Regadenoson—Eye pain—Doxorubicin—uterine cancer	0.00223	0.00238	CcSEcCtD
Regadenoson—Cerebrovascular accident—Epirubicin—uterine cancer	0.00222	0.00237	CcSEcCtD
Regadenoson—Nausea—Progesterone—uterine cancer	0.00222	0.00236	CcSEcCtD
Regadenoson—Pain in extremity—Epirubicin—uterine cancer	0.00218	0.00232	CcSEcCtD
Regadenoson—Feeling abnormal—Dactinomycin—uterine cancer	0.00217	0.00232	CcSEcCtD
Regadenoson—Ill-defined disorder—Etoposide—uterine cancer	0.00217	0.00232	CcSEcCtD
Regadenoson—Gastrointestinal pain—Dactinomycin—uterine cancer	0.00216	0.0023	CcSEcCtD
Regadenoson—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.00215	0.00229	CcSEcCtD
Regadenoson—Rash—Medroxyprogesterone Acetate—uterine cancer	0.00213	0.00227	CcSEcCtD
Regadenoson—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.00213	0.00227	CcSEcCtD
Regadenoson—Headache—Medroxyprogesterone Acetate—uterine cancer	0.00212	0.00226	CcSEcCtD
Regadenoson—Renal impairment—Doxorubicin—uterine cancer	0.00212	0.00226	CcSEcCtD
Regadenoson—Malaise—Etoposide—uterine cancer	0.00211	0.00225	CcSEcCtD
Regadenoson—Abdominal pain—Dactinomycin—uterine cancer	0.00208	0.00222	CcSEcCtD
Regadenoson—Cardiac arrest—Epirubicin—uterine cancer	0.00207	0.00221	CcSEcCtD
Regadenoson—Loss of consciousness—Etoposide—uterine cancer	0.00205	0.00219	CcSEcCtD
Regadenoson—Cerebrovascular accident—Doxorubicin—uterine cancer	0.00205	0.00219	CcSEcCtD
Regadenoson—Cough—Etoposide—uterine cancer	0.00204	0.00218	CcSEcCtD
Regadenoson—Convulsion—Etoposide—uterine cancer	0.00203	0.00216	CcSEcCtD
Regadenoson—Hypertension—Etoposide—uterine cancer	0.00202	0.00215	CcSEcCtD
Regadenoson—Pain in extremity—Doxorubicin—uterine cancer	0.00201	0.00215	CcSEcCtD
Regadenoson—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.00201	0.00214	CcSEcCtD
Regadenoson—Chest pain—Etoposide—uterine cancer	0.00199	0.00212	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	0.00198	0.00211	CcSEcCtD
Regadenoson—Discomfort—Etoposide—uterine cancer	0.00197	0.0021	CcSEcCtD
Regadenoson—Hypersensitivity—Dactinomycin—uterine cancer	0.00194	0.00207	CcSEcCtD
Regadenoson—Cardiac arrest—Doxorubicin—uterine cancer	0.00191	0.00204	CcSEcCtD
Regadenoson—Anaphylactic shock—Etoposide—uterine cancer	0.00191	0.00204	CcSEcCtD
Regadenoson—Abdominal distension—Epirubicin—uterine cancer	0.00189	0.00202	CcSEcCtD
Regadenoson—Asthenia—Dactinomycin—uterine cancer	0.00189	0.00202	CcSEcCtD
Regadenoson—Asthma—Epirubicin—uterine cancer	0.00188	0.00201	CcSEcCtD
Regadenoson—Tachycardia—Etoposide—uterine cancer	0.00186	0.00199	CcSEcCtD
Regadenoson—Skin disorder—Etoposide—uterine cancer	0.00185	0.00198	CcSEcCtD
Regadenoson—Hyperhidrosis—Etoposide—uterine cancer	0.00184	0.00197	CcSEcCtD
Regadenoson—Angina pectoris—Epirubicin—uterine cancer	0.00183	0.00196	CcSEcCtD
Regadenoson—Diarrhoea—Dactinomycin—uterine cancer	0.0018	0.00193	CcSEcCtD
Regadenoson—Hypotension—Etoposide—uterine cancer	0.00178	0.0019	CcSEcCtD
Regadenoson—Abdominal distension—Doxorubicin—uterine cancer	0.00175	0.00187	CcSEcCtD
Regadenoson—Asthma—Doxorubicin—uterine cancer	0.00174	0.00186	CcSEcCtD
Regadenoson—Paraesthesia—Etoposide—uterine cancer	0.00171	0.00183	CcSEcCtD
Regadenoson—Dyspnoea—Etoposide—uterine cancer	0.0017	0.00182	CcSEcCtD
Regadenoson—Somnolence—Etoposide—uterine cancer	0.0017	0.00181	CcSEcCtD
Regadenoson—Angina pectoris—Doxorubicin—uterine cancer	0.0017	0.00181	CcSEcCtD
Regadenoson—Vomiting—Dactinomycin—uterine cancer	0.00168	0.00179	CcSEcCtD
Regadenoson—Rash—Dactinomycin—uterine cancer	0.00166	0.00177	CcSEcCtD
Regadenoson—Renal failure—Epirubicin—uterine cancer	0.00165	0.00176	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Etoposide—uterine cancer	0.00165	0.00176	CcSEcCtD
Regadenoson—Pain—Etoposide—uterine cancer	0.00163	0.00174	CcSEcCtD
Regadenoson—Feeling abnormal—Etoposide—uterine cancer	0.00157	0.00168	CcSEcCtD
Regadenoson—Nausea—Dactinomycin—uterine cancer	0.00157	0.00167	CcSEcCtD
Regadenoson—Gastrointestinal pain—Etoposide—uterine cancer	0.00156	0.00167	CcSEcCtD
Regadenoson—Bradycardia—Epirubicin—uterine cancer	0.00153	0.00164	CcSEcCtD
Regadenoson—Renal failure—Doxorubicin—uterine cancer	0.00153	0.00163	CcSEcCtD
Regadenoson—Urticaria—Etoposide—uterine cancer	0.00152	0.00162	CcSEcCtD
Regadenoson—Abdominal pain—Etoposide—uterine cancer	0.00151	0.00161	CcSEcCtD
Regadenoson—Hypoaesthesia—Epirubicin—uterine cancer	0.0015	0.0016	CcSEcCtD
Regadenoson—Connective tissue disorder—Epirubicin—uterine cancer	0.00148	0.00158	CcSEcCtD
Regadenoson—Bradycardia—Doxorubicin—uterine cancer	0.00142	0.00151	CcSEcCtD
Regadenoson—Eye disorder—Epirubicin—uterine cancer	0.00141	0.0015	CcSEcCtD
Regadenoson—Hypersensitivity—Etoposide—uterine cancer	0.00141	0.0015	CcSEcCtD
Regadenoson—Tinnitus—Epirubicin—uterine cancer	0.0014	0.0015	CcSEcCtD
Regadenoson—Cardiac disorder—Epirubicin—uterine cancer	0.0014	0.00149	CcSEcCtD
Regadenoson—Flushing—Epirubicin—uterine cancer	0.0014	0.00149	CcSEcCtD
Regadenoson—Hypoaesthesia—Doxorubicin—uterine cancer	0.00139	0.00148	CcSEcCtD
Regadenoson—Asthenia—Etoposide—uterine cancer	0.00137	0.00146	CcSEcCtD
Regadenoson—Connective tissue disorder—Doxorubicin—uterine cancer	0.00137	0.00146	CcSEcCtD
Regadenoson—Angiopathy—Epirubicin—uterine cancer	0.00137	0.00146	CcSEcCtD
Regadenoson—Immune system disorder—Epirubicin—uterine cancer	0.00136	0.00145	CcSEcCtD
Regadenoson—Mediastinal disorder—Epirubicin—uterine cancer	0.00136	0.00145	CcSEcCtD
Regadenoson—Mental disorder—Epirubicin—uterine cancer	0.00132	0.00141	CcSEcCtD
Regadenoson—Erythema—Epirubicin—uterine cancer	0.00131	0.0014	CcSEcCtD
Regadenoson—Diarrhoea—Etoposide—uterine cancer	0.00131	0.00139	CcSEcCtD
Regadenoson—Eye disorder—Doxorubicin—uterine cancer	0.0013	0.00139	CcSEcCtD
Regadenoson—Tinnitus—Doxorubicin—uterine cancer	0.0013	0.00139	CcSEcCtD
Regadenoson—Flushing—Doxorubicin—uterine cancer	0.00129	0.00138	CcSEcCtD
Regadenoson—Cardiac disorder—Doxorubicin—uterine cancer	0.00129	0.00138	CcSEcCtD
Regadenoson—Dysgeusia—Epirubicin—uterine cancer	0.00128	0.00137	CcSEcCtD
Regadenoson—Angiopathy—Doxorubicin—uterine cancer	0.00126	0.00135	CcSEcCtD
Regadenoson—Dizziness—Etoposide—uterine cancer	0.00126	0.00135	CcSEcCtD
Regadenoson—Immune system disorder—Doxorubicin—uterine cancer	0.00126	0.00134	CcSEcCtD
Regadenoson—Mediastinal disorder—Doxorubicin—uterine cancer	0.00126	0.00134	CcSEcCtD
Regadenoson—Vision blurred—Epirubicin—uterine cancer	0.00123	0.00132	CcSEcCtD
Regadenoson—Mental disorder—Doxorubicin—uterine cancer	0.00122	0.0013	CcSEcCtD
Regadenoson—Ill-defined disorder—Epirubicin—uterine cancer	0.00122	0.0013	CcSEcCtD
Regadenoson—Vomiting—Etoposide—uterine cancer	0.00121	0.00129	CcSEcCtD
Regadenoson—Erythema—Doxorubicin—uterine cancer	0.00121	0.00129	CcSEcCtD
Regadenoson—Rash—Etoposide—uterine cancer	0.0012	0.00128	CcSEcCtD
Regadenoson—Dermatitis—Etoposide—uterine cancer	0.0012	0.00128	CcSEcCtD
Regadenoson—Headache—Etoposide—uterine cancer	0.0012	0.00128	CcSEcCtD
Regadenoson—Dysgeusia—Doxorubicin—uterine cancer	0.00119	0.00127	CcSEcCtD
Regadenoson—Malaise—Epirubicin—uterine cancer	0.00118	0.00126	CcSEcCtD
Regadenoson—Syncope—Epirubicin—uterine cancer	0.00118	0.00125	CcSEcCtD
Regadenoson—Palpitations—Epirubicin—uterine cancer	0.00116	0.00124	CcSEcCtD
Regadenoson—Loss of consciousness—Epirubicin—uterine cancer	0.00115	0.00123	CcSEcCtD
Regadenoson—Cough—Epirubicin—uterine cancer	0.00114	0.00122	CcSEcCtD
Regadenoson—Vision blurred—Doxorubicin—uterine cancer	0.00114	0.00122	CcSEcCtD
Regadenoson—Convulsion—Epirubicin—uterine cancer	0.00114	0.00121	CcSEcCtD
Regadenoson—Nausea—Etoposide—uterine cancer	0.00113	0.00121	CcSEcCtD
Regadenoson—Hypertension—Epirubicin—uterine cancer	0.00113	0.00121	CcSEcCtD
Regadenoson—Ill-defined disorder—Doxorubicin—uterine cancer	0.00112	0.0012	CcSEcCtD
Regadenoson—Myalgia—Epirubicin—uterine cancer	0.00112	0.00119	CcSEcCtD
Regadenoson—Arthralgia—Epirubicin—uterine cancer	0.00112	0.00119	CcSEcCtD
Regadenoson—Chest pain—Epirubicin—uterine cancer	0.00112	0.00119	CcSEcCtD
Regadenoson—Anxiety—Epirubicin—uterine cancer	0.00111	0.00119	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	0.00111	0.00118	CcSEcCtD
Regadenoson—Discomfort—Epirubicin—uterine cancer	0.0011	0.00118	CcSEcCtD
Regadenoson—Malaise—Doxorubicin—uterine cancer	0.00109	0.00117	CcSEcCtD
Regadenoson—Syncope—Doxorubicin—uterine cancer	0.00109	0.00116	CcSEcCtD
Regadenoson—Palpitations—Doxorubicin—uterine cancer	0.00107	0.00114	CcSEcCtD
Regadenoson—Anaphylactic shock—Epirubicin—uterine cancer	0.00107	0.00114	CcSEcCtD
Regadenoson—Loss of consciousness—Doxorubicin—uterine cancer	0.00107	0.00114	CcSEcCtD
Regadenoson—Cough—Doxorubicin—uterine cancer	0.00106	0.00113	CcSEcCtD
Regadenoson—Shock—Epirubicin—uterine cancer	0.00105	0.00112	CcSEcCtD
Regadenoson—Convulsion—Doxorubicin—uterine cancer	0.00105	0.00112	CcSEcCtD
Regadenoson—Nervous system disorder—Epirubicin—uterine cancer	0.00105	0.00112	CcSEcCtD
Regadenoson—Hypertension—Doxorubicin—uterine cancer	0.00105	0.00112	CcSEcCtD
Regadenoson—Tachycardia—Epirubicin—uterine cancer	0.00104	0.00111	CcSEcCtD
Regadenoson—Skin disorder—Epirubicin—uterine cancer	0.00104	0.00111	CcSEcCtD
Regadenoson—Hyperhidrosis—Epirubicin—uterine cancer	0.00103	0.0011	CcSEcCtD
Regadenoson—Myalgia—Doxorubicin—uterine cancer	0.00103	0.0011	CcSEcCtD
Regadenoson—Chest pain—Doxorubicin—uterine cancer	0.00103	0.0011	CcSEcCtD
Regadenoson—Arthralgia—Doxorubicin—uterine cancer	0.00103	0.0011	CcSEcCtD
Regadenoson—Anxiety—Doxorubicin—uterine cancer	0.00103	0.0011	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	0.00103	0.00109	CcSEcCtD
Regadenoson—Discomfort—Doxorubicin—uterine cancer	0.00102	0.00109	CcSEcCtD
Regadenoson—Hypotension—Epirubicin—uterine cancer	0.000999	0.00107	CcSEcCtD
Regadenoson—Anaphylactic shock—Doxorubicin—uterine cancer	0.00099	0.00106	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Epirubicin—uterine cancer	0.000974	0.00104	CcSEcCtD
Regadenoson—Shock—Doxorubicin—uterine cancer	0.000974	0.00104	CcSEcCtD
Regadenoson—Nervous system disorder—Doxorubicin—uterine cancer	0.00097	0.00104	CcSEcCtD
Regadenoson—Insomnia—Epirubicin—uterine cancer	0.000967	0.00103	CcSEcCtD
Regadenoson—Tachycardia—Doxorubicin—uterine cancer	0.000966	0.00103	CcSEcCtD
Regadenoson—Skin disorder—Doxorubicin—uterine cancer	0.000961	0.00103	CcSEcCtD
Regadenoson—Paraesthesia—Epirubicin—uterine cancer	0.00096	0.00102	CcSEcCtD
Regadenoson—Hyperhidrosis—Doxorubicin—uterine cancer	0.000957	0.00102	CcSEcCtD
Regadenoson—Dyspnoea—Epirubicin—uterine cancer	0.000953	0.00102	CcSEcCtD
Regadenoson—Somnolence—Epirubicin—uterine cancer	0.000951	0.00101	CcSEcCtD
Regadenoson—Hypotension—Doxorubicin—uterine cancer	0.000925	0.000987	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Epirubicin—uterine cancer	0.000923	0.000985	CcSEcCtD
Regadenoson—Pain—Epirubicin—uterine cancer	0.000915	0.000976	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Doxorubicin—uterine cancer	0.000902	0.000962	CcSEcCtD
Regadenoson—Insomnia—Doxorubicin—uterine cancer	0.000895	0.000955	CcSEcCtD
Regadenoson—Paraesthesia—Doxorubicin—uterine cancer	0.000889	0.000948	CcSEcCtD
Regadenoson—Dyspnoea—Doxorubicin—uterine cancer	0.000882	0.000942	CcSEcCtD
Regadenoson—Feeling abnormal—Epirubicin—uterine cancer	0.000881	0.000941	CcSEcCtD
Regadenoson—Somnolence—Doxorubicin—uterine cancer	0.00088	0.000939	CcSEcCtD
Regadenoson—Gastrointestinal pain—Epirubicin—uterine cancer	0.000874	0.000933	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Doxorubicin—uterine cancer	0.000854	0.000912	CcSEcCtD
Regadenoson—Urticaria—Epirubicin—uterine cancer	0.00085	0.000907	CcSEcCtD
Regadenoson—Pain—Doxorubicin—uterine cancer	0.000846	0.000903	CcSEcCtD
Regadenoson—Abdominal pain—Epirubicin—uterine cancer	0.000845	0.000902	CcSEcCtD
Regadenoson—Feeling abnormal—Doxorubicin—uterine cancer	0.000815	0.00087	CcSEcCtD
Regadenoson—Gastrointestinal pain—Doxorubicin—uterine cancer	0.000809	0.000864	CcSEcCtD
Regadenoson—Hypersensitivity—Epirubicin—uterine cancer	0.000788	0.000841	CcSEcCtD
Regadenoson—Urticaria—Doxorubicin—uterine cancer	0.000786	0.000839	CcSEcCtD
Regadenoson—Abdominal pain—Doxorubicin—uterine cancer	0.000782	0.000835	CcSEcCtD
Regadenoson—Asthenia—Epirubicin—uterine cancer	0.000767	0.000819	CcSEcCtD
Regadenoson—Diarrhoea—Epirubicin—uterine cancer	0.000732	0.000781	CcSEcCtD
Regadenoson—Hypersensitivity—Doxorubicin—uterine cancer	0.000729	0.000778	CcSEcCtD
Regadenoson—Asthenia—Doxorubicin—uterine cancer	0.00071	0.000758	CcSEcCtD
Regadenoson—Dizziness—Epirubicin—uterine cancer	0.000707	0.000755	CcSEcCtD
Regadenoson—Vomiting—Epirubicin—uterine cancer	0.00068	0.000726	CcSEcCtD
Regadenoson—Diarrhoea—Doxorubicin—uterine cancer	0.000677	0.000723	CcSEcCtD
Regadenoson—Rash—Epirubicin—uterine cancer	0.000674	0.00072	CcSEcCtD
Regadenoson—Dermatitis—Epirubicin—uterine cancer	0.000674	0.000719	CcSEcCtD
Regadenoson—Headache—Epirubicin—uterine cancer	0.00067	0.000715	CcSEcCtD
Regadenoson—Dizziness—Doxorubicin—uterine cancer	0.000654	0.000698	CcSEcCtD
Regadenoson—Nausea—Epirubicin—uterine cancer	0.000635	0.000678	CcSEcCtD
Regadenoson—Vomiting—Doxorubicin—uterine cancer	0.000629	0.000672	CcSEcCtD
Regadenoson—Rash—Doxorubicin—uterine cancer	0.000624	0.000666	CcSEcCtD
Regadenoson—Dermatitis—Doxorubicin—uterine cancer	0.000623	0.000665	CcSEcCtD
Regadenoson—Headache—Doxorubicin—uterine cancer	0.00062	0.000662	CcSEcCtD
Regadenoson—Nausea—Doxorubicin—uterine cancer	0.000588	0.000627	CcSEcCtD
